This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Clipboard, Search History, and several other advanced features are temporarily unavailable.

[Skip to main page content](#article-details)

![U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)

An official website of the United States government

Here's how you know

![Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)

**The .gov means it’s official.**  
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

![Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)

**The site is secure.**  
The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

[![NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)](https://www.ncbi.nlm.nih.gov/)

[Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F32417270%2F) Show account info

Close

#### Account

Logged in as:  
**username**

- [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/)
- [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/)
- [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/)
- [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/32417270/)

[Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](/myncbi/) [Main Content](#maincontent) [Main Navigation](#)

[![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/080b4ac3-97ae-47fc-ab10-1d08612d1f85/core/images/pubmed-logo-blue.svg)](/)[](# "Show search bar")

Search: 

[](# "Clear search input")Search

[Advanced](/advanced/) [Clipboard](/clipboard/)

[User Guide](/help/)

Save Email

Send to

- [Clipboard](#)
- [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F32417270%2F%23open-bibliography-panel)
- [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F32417270%2F%23open-collections-panel)
- [Citation manager](#)

Display options

Display options

Format Abstract PubMed PMID

## Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV

Create file Cancel

## Email citation

Subject: 1 selected item: 32417270 - PubMed  

To: 

From: 

Format: Summary Summary (text) Abstract Abstract (text)

 MeSH and other data

Send email Cancel

 

### Add to Collections

-  Create a new collection
-  Add to an existing collection

Name your collection: 

Name must be less than 100 characters

Choose a collection:

Unable to load your collection due to an error  
[Please try again](#)

Add Cancel

### Add to My Bibliography

-  My Bibliography

Unable to load your delegates due to an error  
[Please try again](#)

Add Cancel

## Your saved search

Name of saved search: 

Search terms:

[Test search terms](#)

Would you like email updates of new search results?

Saved Search Alert Radio Buttons

-  Yes
-  No

Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/))

Frequency: Monthly Weekly Daily

Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday

Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday

Report format: Summary Summary (text) Abstract Abstract (text) PubMed

Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items

 Send even when there aren't any new results

Optional text in email:

Save Cancel

## Create a file for external citation management software

 

Create file Cancel

## Your RSS Feed

Name of RSS Feed: 

Number of items displayed: 5 10 15 20 50 100

Create RSS Cancel

RSS Link  Copy

### Full text links

 [![full text provider logo](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science](https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(20)30105-4 "See full text options at Elsevier Science") [Free PMC article](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32417270/ "Free full text at PubMed Central")

[Full text links](#)

### Actions

Cite

Collections

Add to Collections

- Create a new collection
- Add to an existing collection

Name your collection: 

Name must be less than 100 characters

Choose a collection:

Unable to load your collection due to an error  
[Please try again](#)

Add Cancel

Display options

Display options

Format AbstractPubMedPMID

### Share

- [](http://twitter.com/intent/tweet?text=MERTK%20in%20cancer%20therapy%3A%20Targeting%20the%20receptor%20tyrosine%20kinase%20in%20tumor%20cells%20and%20the%20immune%20system%20https%3A//pubmed.ncbi.nlm.nih.gov/32417270/ "Share article on Twitter")
- [](http://www.facebook.com/sharer/sharer.php?u=https%3A//pubmed.ncbi.nlm.nih.gov/32417270/ "Share article on Facebook")
- Permalink
    
    Copy
    

### Page navigation

- [Title & authors](#heading)
- [Erratum in](#linked-correction-forward)
- [Abstract](#abstract)
- [Conflict of interest statement](#conflict-of-interest)
- [Figures](#figures)
- [Cited by](#citedby)
- [Publication types](#publication-types)
- [MeSH terms](#mesh-terms)
- [Substances](#substances)
- [Grant support](#grants)
- [LinkOut - more resources](#linkout)

Title & authors Erratum in Abstract Conflict of interest statement Figures Cited by Publication types MeSH terms Substances Grant support LinkOut - more resources

Review

Pharmacol Ther

Actions

- [Search in PubMed](/?term=%22Pharmacol+Ther%22%5Bjour%5D&sort=date&sort_order=desc)
- [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Pharmacol+Ther%22%5BTitle+Abbreviation%5D)
- [Add to Search](#)

. 2020 Sep;213:107577.

doi: 10.1016/j.pharmthera.2020.107577. Epub 2020 May 14.

# MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system

[Justus M Huelse](/?term=Huelse+JM&cauthor_id=32417270)  [1](#full-view-affiliation-1 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.") , [Diana M Fridlyand](/?term=Fridlyand+DM&cauthor_id=32417270)  [1](#full-view-affiliation-1 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.") , [Shelton Earp](/?term=Earp+S&cauthor_id=32417270)  [2](#full-view-affiliation-2 "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.") , [Deborah DeRyckere](/?term=DeRyckere+D&cauthor_id=32417270)  [1](#full-view-affiliation-1 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.") , [Douglas K Graham](/?term=Graham+DK&cauthor_id=32417270)  [3](#full-view-affiliation-3 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA. Electronic address: Douglas.Graham@choa.org.")

Affiliations Expand

### Affiliations

- 1 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.
- 2 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
- 3 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA. Electronic address: Douglas.Graham@choa.org.

- PMID: **32417270**
- PMCID: [PMC9847360](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9847360/)
- DOI: [10.1016/j.pharmthera.2020.107577](https://doi.org/10.1016/j.pharmthera.2020.107577)

Free PMC article

Item in Clipboard

Review

# MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system

Justus M Huelse et al. Pharmacol Ther. 2020 Sep.

Free PMC article

Show details

Display options

Display options

Format Abstract PubMed PMID

Pharmacol Ther

Actions

- [Search in PubMed](/?term=%22Pharmacol+Ther%22%5Bjour%5D&sort=date&sort_order=desc)
- [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Pharmacol+Ther%22%5BTitle+Abbreviation%5D)
- [Add to Search](#)

. 2020 Sep;213:107577.

doi: 10.1016/j.pharmthera.2020.107577. Epub 2020 May 14.

### Authors

[Justus M Huelse](/?term=Huelse+JM&cauthor_id=32417270)  [1](#short-view-affiliation-1 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.") , [Diana M Fridlyand](/?term=Fridlyand+DM&cauthor_id=32417270)  [1](#short-view-affiliation-1 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.") , [Shelton Earp](/?term=Earp+S&cauthor_id=32417270)  [2](#short-view-affiliation-2 "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.") , [Deborah DeRyckere](/?term=DeRyckere+D&cauthor_id=32417270)  [1](#short-view-affiliation-1 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.") , [Douglas K Graham](/?term=Graham+DK&cauthor_id=32417270)  [3](#short-view-affiliation-3 "Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA. Electronic address: Douglas.Graham@choa.org.")

### Affiliations

- 1 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.
- 2 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
- 3 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA. Electronic address: Douglas.Graham@choa.org.

- PMID: **32417270**
- PMCID: [PMC9847360](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9847360/)
- DOI: [10.1016/j.pharmthera.2020.107577](https://doi.org/10.1016/j.pharmthera.2020.107577)

Item in Clipboard

Full text links Cite

Display options

Display options

Format AbstractPubMedPMID

## Erratum in

- [Corrigendum to "MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system" [Pharmacology & Therapeutics 213 (2020) 107577].](/33714535/)
    
    Huelse JM, Fridlyand DM, Earp S, DeRyckere D, Graham DK. Huelse JM, et al. Pharmacol Ther. 2021 Sep;225:107822. doi: 10.1016/j.pharmthera.2021.107822. Epub 2021 Mar 10. Pharmacol Ther. 2021. PMID: 33714535 No abstract available.
    

## Abstract

The receptor tyrosine kinase MERTK is aberrantly expressed in numerous human malignancies, and is a novel target in cancer therapeutics. Physiologic roles of MERTK include regulation of tissue homeostasis and repair, innate immune control, and platelet aggregation. However, aberrant expression in a wide range of liquid and solid malignancies promotes neoplasia via growth factor independence, cell cycle progression, proliferation and tumor growth, resistance to apoptosis, and promotion of tumor metastases. Additionally, MERTK signaling contributes to an immunosuppressive tumor microenvironment via induction of an anti-inflammatory cytokine profile and regulation of the PD-1 axis, as well as regulation of macrophage, myeloid-derived suppressor cell, natural killer cell and T cell functions. Various MERTK-directed therapies are in preclinical development, and clinical trials are underway. In this review we discuss MERTK inhibition as an emerging strategy for cancer therapy, focusing on MERTK expression and function in neoplasia and its role in mediating resistance to cytotoxic and targeted therapies as well as in suppressing anti-tumor immunity. Additionally, we review preclinical and clinical pharmacological strategies to target MERTK.

**Keywords:** MERTK; anti-tumor immunity; clinical trials; neoplasia; preclinical agents.

Copyright © 2020 Elsevier Inc. All rights reserved.

## Conflict of interest statement

Declaration of Competing Interest Diana Fridlyand – The author declares that there are no conflicts of interest Justus Huelse – The author declares that there are no conflicts of interest Shelton Earp – The author holds equity in Meryx incorporated and is on the Meryx board of directors Deborah DeRyckere – The author holds equity in Meryx incorporated Douglas K. Graham – The author holds equity in Meryx incorporated and is on the Meryx board of directors

## Figures

 [![Figure 1:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9847360/bin/nihms-1601552-f0001.gif)](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9847360/bin/nihms-1601552-f0001.jpg) 

**

Figure 1:. MERTK Regulating Hallmarks of Cancer

**

**

Figure 1:. MERTK Regulating Hallmarks of Cancer

**

MERTK mediates many hallmarks of cancer including resistance…

**Figure 1:. MERTK Regulating Hallmarks of Cancer**

MERTK mediates many hallmarks of cancer including resistance to cell death, evasion of growth suppressors, induction of drug resistance, avoidance of immune destruction, sustaining of proliferative signaling, as well as activation of invasion and metastases. In some contexts, MERTK signaling may be transforming (not shown). Hence, targeting MERTK to inhibit these oncogenic functions represents an attractive strategy for cancer therapies. BAX (Bcl-2-associated X), PUMA (p53 upregulated modulator of apoptosis), BCL-XL (B-cell lymphoma-extra-large), BCL-2 (B-cell lymphoma 2), MCL1, (myeloid cell leukemia 1), ACK1 (activated CDC42 kinase 1), WWOX (WW domain-containing oxidoreductase), YAP (yes-associated protein 1), TAZ (transcriptional coactivator with PDZ-binding motif), PD-1 (programmed cell death protein 1) PD-L1 (programmed cell death 1 ligand 1) M1/2 (macrophage polarization 1/2)

 [![Figure 2:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9847360/bin/nihms-1601552-f0002.gif)](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9847360/bin/nihms-1601552-f0002.jpg) 

**

Figure 2:. MERTK Signaling in Cancer

**

MERTK…

**

Figure 2:. MERTK Signaling in Cancer

**

MERTK activation and subsequent signaling regulates numerous oncogenic pathways.…

**Figure 2:. MERTK Signaling in Cancer**

MERTK activation and subsequent signaling regulates numerous oncogenic pathways. Depending on cancer type, context, and the specific ligand (GAS6, PROS1, Tubby, TULP-1 or Galectin-3), MERTK signaling results in increased proliferation, anti-apoptosis and survival, migration and metastasis, anchorage-independent growth, cancer stem cell (CSC) maintenance, as well as expression of the immune checkpoint protein PD-L1. In certain contexts, MERTK signaling may be transforming. MERTK has also been found in the nucleus of leukemic cells but the function remains unknown. GAS6 (growth arrest-specific 6), PROS1 (vitamin K-dependent protein S), TULP-1 (tubby-like protein 1), MEK (mitogen-activated protein kinase), ERK (extracellular signal-regulated kinases), PI3K (phosphatidylinositol 3-kinases), SAV1 (protein salvador homolog 1), BAD (BCL-2 associated agonist of cell death), mTOR (mammalian target of rapamycin), BCL-2 (B-cell lymphoma 2), MCL1, (myeloid cell leukemia 1), BCL-XL (B-cell lymphoma-extra large), PUMA (p53 upregulated modulator of apoptosis), BAX (Bcl-2-associated X), FAK1 (focal adhesion kinase 1), RHOA (Ras homolog family member A), RAC (Ras-related C3 botulinum toxin substrate), NF-ĸB (nuclear factor-ĸB), CREB (cAMP-responsive element-binding protein), ATF1 (activating transcription factor 1), JAK (Janus kinase), STAT 3/5/6 (signal transducer and activator of transcription 3/5/6), PD-L1 (programmed cell death 1 ligand 1) ACK1 (activated CDC42 kinase 1), WWOX (WW domain-containing oxidoreductase), YAP (yes-associated protein 1), TAZ (transcriptional coactivator with PDZ-binding motif), SRC (sarcoma), p-SRC (phospho-SRC), KRAS (Kirsten rat sarcoma viral oncogene homolog), SOX2 (Sry-related HMG box), Zeb1 (Zinc finger E-box-binding homeobox 1),

 [![Figure 3:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9847360/bin/nihms-1601552-f0003.gif)](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9847360/bin/nihms-1601552-f0003.jpg) 

**

Figure 3:. MERTK Immune Functions in Cancer

**

**

Figure 3:. MERTK Immune Functions in Cancer

**

MERTK signaling in tumor and immune cells contributes…

**Figure 3:. MERTK Immune Functions in Cancer**

MERTK signaling in tumor and immune cells contributes to an immunosuppressive tumor microenvironment that favors tumor growth. LEFT: MERTK signaling and immune functions in cells of the tumor microenvironment MERTK signaling in macrophages induces an immunosuppressive M2 phenotype (Stanford, et al., 2014). Tumor cells can release the MERTK ligands GAS6 and PROS1 (Ubil, et al., 2018) and tumor cell-derived PROS1 inhibits the expression of M1 polarization-associated genes in macrophages (Ubil, et al., 2018). Additionally, tumor cells can release the cytokines IL-10 and M-CSF, which induce autocrine GAS6 production in macrophages (S. Loges, et al., 2010). Furthermore, MERTK-dependent efferocytosis of apoptotic tumor cells induces macrophages to release the anti-inflammatory cytokines IL-10, IL-4, TGF-β (Crittenden, et al., 2016; Stanford, et al., 2014) and to produce increased _Mertk_, _Gas6_ and _Pros1_ mRNA, forming a positive feedback loop (Crittenden, et al., 2016). Activation of MERTK through binding of its ligands and PtdSer (which may be exposed on apoptotic tumor cells) induces expression of the immune checkpoint protein PD-L1 on cancer cells (Kasikara, et al., 2017). Furthermore, MERTK signaling can induce PD-L1 and PD-L2 expression on myeloid cells (shown here: macrophages) (Lee-Sherick, et al., 2018). Binding of PD-L1 or PD-L2 to PD-1 on T-cells inhibits T-cell anti-tumor activity. TAM (TYRO3, AXL, MERTK) signaling suppresses NK cell function but the individual role of MERTK is not understood (Chirino, et al., 2019; Paolino, et al., 2014). Furthermore, MERTK signaling induces immunosuppressive and migratory capacities in MDSCs (Caetano, et al., 2019; Holtzhausen, et al., 2019). In contrast, MERTK signaling enhances NKT cell activity (Behrens, et al., 2003) and may have an immune-stimulatory role in activated human T cells (Cabezon, et al., 2015; Peeters, et al., 2019). RIGHT: Immune effects of MERTK signaling in the tumor microenvironment. Effects of MERTK signaling include macrophage M2 polarization (Crittenden, et al., 2016; Stanford, et al., 2014), induction of an immunosuppressive cytokine profile (Cook, et al., 2013; Stanford, et al., 2014) and altered immune cell infiltration (Caetano, et al., 2019; Cook, et al., 2013; Holtzhausen, et al., 2019; Lee-Sherick, et al., 2018; Werfel & Cook, 2018). GAS6 (growth arrest-specific 6), PROS1 (vitamin K-dependent protein S), IL-4/6/10/12p40/13 (interleukin 4/6/10/12p40/13), M-CSF (macrophage colony-stimulating factor), M1/2 (macrophage polarization 1/2) PtdSer (phosphatidylserine), PI3K (phosphatidylinositol 3-kinases), PD-L1/2 (programmed cell death 1 ligand 1/2), PD-1 (programmed cell death protein 1), TGF-β (transforming growth factor-β), NKT cell (natural killer T cell), NK cell (natural killer cell), MDSCs (myeloid-derived suppressor cells), MΦ (macrophage), DC (dendritic cells), CD8+ (CD8+ T cell), Tregs (regulatory T cells)

[See this image and copyright information in PMC](#)

## Cited by

- [Editorial: The key role of Mer receptor tyrosine kinase: where inflammation ends and fibrosis begins.](/37529052/)
    
    Zizzo G, Cohen PL. Zizzo G, et al. Front Immunol. 2023 Jul 17;14:1251577. doi: 10.3389/fimmu.2023.1251577. eCollection 2023. Front Immunol. 2023. PMID: 37529052 Free PMC article. No abstract available.
    
- [Glycolytic Genes Predict Immune Status and Prognosis Non-Small-Cell Lung Cancer Patients with Radiotherapy and Chemotherapy.](/37101691/)
    
    Zhao T, Shao J, Liu J, Wang Y, Chen J, He S, Wang G. Zhao T, et al. Biomed Res Int. 2023 Apr 17;2023:4019091. doi: 10.1155/2023/4019091. eCollection 2023. Biomed Res Int. 2023. PMID: 37101691 Free PMC article.
    
- [Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity.](/36966130/)
    
    Zhuang WR, Wang Y, Nie W, Lei Y, Liang C, He J, Zuo L, Huang LL, Xie HY. Zhuang WR, et al. Nat Commun. 2023 Mar 25;14(1):1675. doi: 10.1038/s41467-023-37369-0. Nat Commun. 2023. PMID: 36966130 Free PMC article.
    
- [TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment.](/36693679/)
    
    Park M, Kuen DS, Park J, Choi M, Kim Y, Roh EC, Choi YJ, Kim YG, Chung Y, Cho SY, Kang KW. Park M, et al. J Immunother Cancer. 2023 Jan;11(1):e006084. doi: 10.1136/jitc-2022-006084. J Immunother Cancer. 2023. PMID: 36693679 Free PMC article.
    
- [Single-cell computational machine learning approaches to immune-mediated inflammatory disease: New tools uncover novel fibroblast and macrophage interactions driving pathogenesis.](/36685542/)
    
    Fritz D, Inamo J, Zhang F. Fritz D, et al. Front Immunol. 2023 Jan 4;13:1076700. doi: 10.3389/fimmu.2022.1076700. eCollection 2022. Front Immunol. 2023. PMID: 36685542 Free PMC article. Review.
    

See all "Cited by" articles

## Publication types

- Research Support, N.I.H., Extramural
    
    Actions
    
    - [Search in PubMed](/?term=%22Research+Support%2C+N.I.H.%2C+Extramural%22%5Bpt%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Research+Support%2C+N.I.H.%2C+Extramural)
    - [Add to Search](#)
    
- Review
    
    Actions
    
    - [Search in PubMed](/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Review)
    - [Add to Search](#)
    

## MeSH terms

- Animals
    
    Actions
    
    - [Search in PubMed](/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Animals)
    - [Add to Search](#)
    
- Antineoplastic Agents / pharmacology
    
    Actions
    
    - [Search in PubMed](/?term=%22Antineoplastic+Agents%2Fpharmacology%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents)
    - [Add to Search](#)
    
- Drug Resistance, Neoplasm
    
    Actions
    
    - [Search in PubMed](/?term=%22Drug+Resistance%2C+Neoplasm%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Resistance%2C+Neoplasm)
    - [Add to Search](#)
    
- Humans
    
    Actions
    
    - [Search in PubMed](/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Humans)
    - [Add to Search](#)
    
- Molecular Targeted Therapy
    
    Actions
    
    - [Search in PubMed](/?term=%22Molecular+Targeted+Therapy%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Molecular+Targeted+Therapy)
    - [Add to Search](#)
    
- Neoplasms / drug therapy*
    
    Actions
    
    - [Search in PubMed](/?term=%22Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms)
    - [Add to Search](#)
    
- Neoplasms / enzymology
    
    Actions
    
    - [Search in PubMed](/?term=%22Neoplasms%2Fenzymology%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms)
    - [Add to Search](#)
    
- Neoplasms / pathology
    
    Actions
    
    - [Search in PubMed](/?term=%22Neoplasms%2Fpathology%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms)
    - [Add to Search](#)
    
- Protein Kinase Inhibitors / pharmacology*
    
    Actions
    
    - [Search in PubMed](/?term=%22Protein+Kinase+Inhibitors%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Protein+Kinase+Inhibitors)
    - [Add to Search](#)
    
- Tumor Microenvironment
    
    Actions
    
    - [Search in PubMed](/?term=%22Tumor+Microenvironment%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Tumor+Microenvironment)
    - [Add to Search](#)
    
- c-Mer Tyrosine Kinase / antagonists & inhibitors*
    
    Actions
    
    - [Search in PubMed](/?term=%22c-Mer+Tyrosine+Kinase%2Fantagonists+and+inhibitors%22%5BMAJR%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=c-Mer+Tyrosine+Kinase)
    - [Add to Search](#)
    
- c-Mer Tyrosine Kinase / metabolism
    
    Actions
    
    - [Search in PubMed](/?term=%22c-Mer+Tyrosine+Kinase%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=c-Mer+Tyrosine+Kinase)
    - [Add to Search](#)
    

## Substances

- Antineoplastic Agents
    
    Actions
    
    - [Search in PubMed](/?term=%22Antineoplastic+Agents%22%5Bnm%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antineoplastic+Agents%22)
    - [Add to Search](#)
    
- Protein Kinase Inhibitors
    
    Actions
    
    - [Search in PubMed](/?term=%22Protein+Kinase+Inhibitors%22%5Bnm%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22Protein+Kinase+Inhibitors%22)
    - [Add to Search](#)
    
- MERTK protein, human
    
    Actions
    
    - [Search in PubMed](/?term=%22MERTK+protein%2C+human%22%5Bnm%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22MERTK+protein%2C+human%22)
    - [Add to Search](#)
    
- c-Mer Tyrosine Kinase
    
    Actions
    
    - [Search in PubMed](/?term=%22c-Mer+Tyrosine+Kinase%22%5Bnm%5D&sort=date&sort_order=desc)
    - [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22c-Mer+Tyrosine+Kinase%22)
    - [Add to Search](#)
    

## Grant support

- [P50 CA217691/CA/NCI NIH HHS/United States](/?term=P50+CA217691%2FCA%2FNCI+NIH+HHS%2FUnited+States%5BGrant+Number%5D&sort=date&sort_order=desc "All articles for grant P50 CA217691/CA/NCI NIH HHS/United States")
- [T32 HL139443/HL/NHLBI NIH HHS/United States](/?term=T32+HL139443%2FHL%2FNHLBI+NIH+HHS%2FUnited+States%5BGrant+Number%5D&sort=date&sort_order=desc "All articles for grant T32 HL139443/HL/NHLBI NIH HHS/United States")

## LinkOut - more resources

- ### Full Text Sources
    
    - [Elsevier Science](https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(20)30105-4)
    - [Europe PubMed Central](https://europepmc.org/abstract/MED/32417270)
    - [Ovid Technologies, Inc.](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=32417270.ui)
    - [PubMed Central](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32417270/)
- ### Other Literature Sources
    
    - [The Lens - Patent Citations](https://www.lens.org/lens/search/patent/list?q=citation_id:32417270)
- ### Medical
    
    - [MedlinePlus Health Information](https://medlineplus.gov/cancerchemotherapy.html)
- ### Miscellaneous
    
    - [NCI CPTAC Assay Portal](https://assays.cancer.gov/non-CPTAC-3409)

**Full text links** [x]

 [![full text provider logo](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science](https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(20)30105-4 "See full text options at Elsevier Science") [Free PMC article](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32417270/ "Free full text at PubMed Central")

[x]

Cite

Copy

 Download .nbib

Format: AMA APA MLA NLM

**Send To**

- [Clipboard](#)
- [Email](#)
- [Save](#)
- [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F32417270%2F%23open-bibliography-panel)
- [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F32417270%2F%23open-collections-panel)
- [Citation Manager](#)

[x]

NCBI Literature Resources

[MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](/disclaimer/)

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI

[](https://twitter.com/ncbi) [](https://www.facebook.com/ncbi.nlm) [](https://www.linkedin.com/company/ncbinlm) [](https://github.com/ncbi) [](https://ncbiinsights.ncbi.nlm.nih.gov/)

[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)

- [ ](https://twitter.com/NLM_NIH)
- [ ](https://www.facebook.com/nationallibraryofmedicine)
- [ ](https://www.youtube.com/user/NLMNIH)

National Library of Medicine  
[8600 Rockville Pike  
Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)

[Web Policies](https://www.nlm.nih.gov/web_policies.html)  
[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  
[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)

[Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE)  
[Accessibility](https://www.nlm.nih.gov/accessibility.html)  
[Careers](https://www.nlm.nih.gov/careers/careers.html)

- [NLM](//www.nlm.nih.gov/)
- [NIH](https://www.nih.gov/)
- [HHS](https://www.hhs.gov/)
- [USA.gov](https://www.usa.gov/)